ABSTRACT
SCOPE: The article investigates the FADS1 rs174550 genotype interaction with dietary intakes of high linoleic acid (LA) and high alpha-linolenic acid (ALA) on the response of fatty acid composition of plasma phospholipids (PLs), and of markers of low-grade inflammation and glucose-insulin homeostasis. METHODS AND RESULTS: One-hundred thirty homozygotes men for FADS1 rs174550 SNP (TT and CC genotypes) were randomized to an 8-week intervention with either LA- or ALA-enriched diet (13 E% PUFA). The source of LA and ALA are 30-50 mL of sunflower oil (SFO, 62-63% LA) and Camelina sativa oil (CSO, 30- are randomized to an 35% ALA), respectively. In the SFO arm, there is a significant genotype x diet interaction for the proportion of arachidonic acid in plasma phospholipids (p < 0.001), disposition index (DI30 ) (p = 0.039), and for serum high-sensitive c-reactive protein (hs-CRP, p = 0.029) after excluding the participants with hs-CRP concentration of >10 mg L-1 and users of statins or anti-inflammatory therapy. In the CSO arm, there are significant genotype x diet interactions for n-3 polyunsaturated fatty acids, but not for the clinical characteristics. CONCLUSIONS: The FADS1 genotype modifies the response to high PUFA diets, especially to high-LA diet. These findings suggest that approaches considering FADS variation may be useful in personalized dietary counseling.
Subject(s)
Fatty Acid Desaturases/genetics , Linoleic Acid/pharmacokinetics , alpha-Linolenic Acid/pharmacokinetics , Aged , Blood Glucose/metabolism , Delta-5 Fatty Acid Desaturase , Fatty Acids, Omega-3/pharmacokinetics , Genotype , Humans , Inflammation/blood , Male , Middle Aged , Phospholipids/blood , Plant Oils/chemistry , Plant Oils/pharmacokinetics , Polymorphism, Single Nucleotide , Sunflower Oil/chemistry , Sunflower Oil/pharmacokineticsABSTRACT
Stroke severely impairs quality of life and has a high mortality rate. On the other hand, dietary docosahexaenoic acid (DHA) prevents neuronal damage. In this review, we describe the effects of dietary DHA on ischemic stroke-associated neuronal damage and its role in stroke prevention. Recent epidemiological studies have been conducted to analyze stroke prevention through DHA intake. The effects of dietary intake and supply of DHA to neuronal cells, DHA-mediated inhibition of neuronal damage, and its mechanism, including the effects of the DHA metabolite, neuroprotectin D1 (NPD1), were investigated. These studies revealed that DHA intake was associated with a reduced risk of stroke. Moreover, studies have shown that DHA intake may reduce stroke mortality rates. DHA, which is abundant in fish oil, passes through the blood-brain barrier to accumulate as a constituent of phospholipids in the cell membranes of neuronal cells and astrocytes. Astrocytes supply DHA to neuronal cells, and neuronal DHA, in turn, activates Akt and Raf-1 to prevent neuronal death or damage. Therefore, DHA indirectly prevents neuronal damage. Furthermore, NDP1 blocks neuronal apoptosis. DHA, together with NPD1, may block neuronal damage and prevent stroke. The inhibitory effect on neuronal damage is achieved through the antioxidant (via inducing the Nrf2/HO-1 system) and anti-inflammatory effects (via promoting JNK/AP-1 signaling) of DHA.
Subject(s)
Brain Damage, Chronic/prevention & control , Docosahexaenoic Acids/therapeutic use , Ischemic Stroke/diet therapy , Nerve Degeneration/prevention & control , Stroke/prevention & control , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacokinetics , Anti-Inflammatory Agents/therapeutic use , Antioxidants/administration & dosage , Antioxidants/pharmacokinetics , Antioxidants/therapeutic use , Apoptosis/drug effects , Biological Availability , Biological Transport , Blood-Brain Barrier , Brain Damage, Chronic/etiology , Dietary Fats/administration & dosage , Dietary Fats/pharmacokinetics , Dietary Fats/therapeutic use , Docosahexaenoic Acids/administration & dosage , Docosahexaenoic Acids/metabolism , Docosahexaenoic Acids/pharmacokinetics , Docosahexaenoic Acids/pharmacology , Fatty Acid-Binding Proteins/physiology , Fish Oils/administration & dosage , Fish Oils/pharmacokinetics , Humans , Incidence , Ischemic Stroke/complications , Ischemic Stroke/epidemiology , Membrane Lipids/metabolism , Mice , Neoplasm Proteins/physiology , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Plant Oils/administration & dosage , Plant Oils/pharmacokinetics , Signal Transduction/drug effects , Symporters/deficiency , Symporters/physiology , alpha-Linolenic Acid/pharmacokineticsABSTRACT
The aim of this study was to investigate the bioavailability and bioactivity of perilla (Perilla frutescens) oil nanoemulsions prepared at different homogenization pressures by measuring the weight, fatty acid profile, and antioxidant and anti-inflammatory properties in rats. The high-pressure homogenization significantly reduced the particle size of perilla oil nanoemulsions and enhanced their stability, and the minimum particle size was 293.87 ± 6.55 nm at 120 MPa. There was an increase in the weight and fatty acid levels in the plasma and liver of test group rats. The highest glutathione (GSH) and the lowest malondialdehyde (MDA) levels of 18.76 ± 10.51 mg GSH/g prot and 20.27 ± 2.46 nmol/mg prot, respectively, were recorded in rats administrated perilla oil nanoemulsions prepared at 120 MPa. However, there was no significant difference in superoxide dismutase activity (SOD) between the groups. The interferon-gamma (IL-γ), interleukin-1 beta (IL-1ß), IL-6 (interleukin-6), and IL-8 (interleukin-8) levels in the test groups were lower than those in the blank and control groups at 8 hr after lipopolysaccharide injection. The IL-1ß, IL-6, and IL-8 levels were 49.52 ± 14.06, 90.13 ± 6.04, and 419.71 ± 32.03 ng/L, respectively, in rats treated with perilla oil nanoemulsions prepared at 120 MPa. Both perilla oil and its nanoemulsions decreased estradiol levels and damaged the ovaries. Overall, our findings show that the test nanoemulsions enhanced the bioavailability of perilla oil, which resulted in enhanced antioxidant and anti-inflammatory responses; thus, we provide a new approach to deliver perilla oil. PRACTICAL APPLICATION: Nanoemulsions can be used to deliver drugs and bioactive compounds, and perilla oil nanoemulsions can be used in healthcare products and beverage industries.
Subject(s)
Perilla frutescens/chemistry , alpha-Linolenic Acid/pharmacology , Animals , Anti-Inflammatory Agents , Antioxidants/pharmacology , Biological Availability , Cytokines/genetics , Cytokines/metabolism , Emulsions , Estradiol/metabolism , Fatty Acids , Female , Gene Expression Regulation/drug effects , Male , Nanostructures/chemistry , Ovary/drug effects , Particle Size , Plant Oils/chemistry , Plant Oils/pharmacokinetics , Plant Oils/pharmacology , Plant Oils/toxicity , Rats , alpha-Linolenic Acid/chemistry , alpha-Linolenic Acid/pharmacokinetics , alpha-Linolenic Acid/toxicityABSTRACT
SCOPE: To compare the effects of supplementary eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) versus α-linolenic acid (ALA) on lipid profiles, inflammatory status, and fatty acid composition of peripheral blood mononuclear cells (PBMCs) in hypercholesterolemic adults. METHODS AND RESULTS: A randomized, controlled, double-blind trial is conducted to examine the effects of consumption of control oil, 4.2 g/d ALA, 7.2 g/d ALA, 1.8 g/d DHA+EPA, or 3.6 g/d EPA+DHA for 12 weeks on lipid profiles, fatty acid composition of PBMCs and in vitro production of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) by PBMCs in 123 subjects with hypercholesteremia. After the intervention, subjects who receive a low and high dose of DHA/EPA experience 11.99% and 15.78% decreases in triglycerides which is significantly different from that of the control group (p < 0.05). The in vitro study indicates that supplementation of high-dose DHA+EPA induces the greatest decrease of IL-6 production by PBMCs relative to other groups (p = 0.046). ALA intervention significantly increases the PBMCs composition of ALA but not EPA/DHA. CONCLUSION: EPA+DHA, but not ALA, improves lipids and inflammation status in hypercholesterolemic adults. Supplementation of ALA does not increase the PBMCs composition of EPA/DHA in middle-aged to elderly Chinese.
Subject(s)
Docosahexaenoic Acids/pharmacology , Eicosapentaenoic Acid/pharmacology , Hypercholesterolemia/diet therapy , Inflammation/diet therapy , Lipids/blood , alpha-Linolenic Acid/pharmacology , Adult , Aged , Body Mass Index , Dietary Supplements , Double-Blind Method , Fatty Acids/blood , Fatty Acids, Omega-3/metabolism , Fatty Acids, Omega-3/pharmacokinetics , Female , Humans , Hypercholesterolemia/blood , Inflammation/blood , Interleukin-6/blood , Male , Middle Aged , Placebo Effect , Placebos , Triglycerides/blood , Tumor Necrosis Factor-alpha/blood , alpha-Linolenic Acid/pharmacokineticsABSTRACT
SCOPE: The study aims at identifying 1) the most sensitive compartment among plasma phospholipids, erythrocytes, and LDL for studying alpha-linolenic acid (ALA) conversion, and 2) whether ALA incorporation and conversion is saturable after administration of 13 C-labeled ALA-rich linseed oil (LO). The effect of a daily intake of 7 g nonlabeled LO (>43% w/w ALA) for 1 month after bolus administration of 7 g 13 C-labeled LO on day 1, and for 2 months after bolus administration of 7 g 13 C-labeled LO on day 1 and day 29 on 13 C-ALA incorporation and conversion into its higher homologs is investigated in healthy volunteers. METHODS AND RESULTS: Incorporation and conversion of LO-derived 13 C-labeled ALA is quantified by applying compartmental modeling. After bolus administration, a fractional conversion of approximately 30% from 13 C-ALA to 13 C-DHA is calculated as reflected by the LDL compartment. Treatment with LO for 8 weeks induces a mean reduction of 13 C-ALA conversion to 13 C-DHA by 48% as reflected by the LDL compartment, and a mean reduction of the 13 C-ALA incorporation into LDL by 46%. CONCLUSION: A 2-month dietary intake of a high dose of LO is sufficient to reach saturation of ALA incorporation into LDL particles, which are responsible for ALA distribution in the body.
Subject(s)
Linseed Oil/pharmacokinetics , Phospholipids/blood , alpha-Linolenic Acid/administration & dosage , alpha-Linolenic Acid/pharmacokinetics , Adult , Body Weight/drug effects , Carbon Isotopes/pharmacokinetics , Docosahexaenoic Acids/blood , Docosahexaenoic Acids/metabolism , Eicosapentaenoic Acid/blood , Eicosapentaenoic Acid/metabolism , Erythrocytes/chemistry , Erythrocytes/drug effects , Fatty Acids, Omega-3/analysis , Healthy Volunteers , Humans , Linseed Oil/pharmacology , Lipoproteins, IDL/blood , Male , Models, BiologicalABSTRACT
Chronic inflammation, mediated in large part by proinflammatory macrophage populations, contributes directly to the induction and perpetuation of metabolic diseases, including obesity, insulin resistance and type 2 diabetes. Polyunsaturated fatty acids (PUFAs) can have profound effects on inflammation through the formation of bioactive oxygenated metabolites called oxylipins. The objective of this study was to determine if exposure to the dietary omega-3 PUFA α-linolenic acid (ALA) can dampen the inflammatory properties of classically activated (M1-like) macrophages derived from the human THP-1 cell line and to examine the accompanying alterations in oxylipin secretion. We find that ALA treatment leads to a reduction in lipopolysaccharide (LPS)-induced interleukin (IL)-1ß, IL-6 and tumor necrosis factor-α production. Although ALA is known to be converted to longer-chain PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), DHA oxylipins were reduced overall by ALA treatment, as was LPS-induced secretion of EPA oxylipins. In contrast, we observed profound increases in oxylipins directly derived from ALA. Lipoxygenase products of linoleic acid were also dramatically increased, and LPS-induced production of AA oxylipins, particularly prostaglandin D2, was reduced. These results suggest that ALA may act to dampen the inflammatory phenotype of M1-like macrophages by a unique set of mechanisms distinct from those used by the long-chain omega-3 fatty acids EPA and DHA. Thus, there is strong rationale for investigating the functions of ALA oxylipins and lesser-known LA oxylipins since they hold promise as anti-inflammatory agents.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Linoleic Acid/pharmacology , Macrophages/drug effects , Oxylipins/metabolism , alpha-Linolenic Acid/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Cell Line , Cell Polarity/drug effects , Cytochrome P-450 Enzyme System/metabolism , Cytokines/metabolism , Humans , Linoleic Acid/pharmacokinetics , Lipopolysaccharides/toxicity , Macrophages/metabolism , Protein-Lysine 6-Oxidase/metabolism , Reproducibility of Results , alpha-Linolenic Acid/pharmacokineticsABSTRACT
The oral bioavailability of felodipine, a dihydropyridine calcium channel antagonist, is about 15%. This may be due to poor water solubility, and a lower intestinal permeability than a BCS class I drug, and hepatic first-pass metabolism of the drug. Many drugs are unpopular due to solubility issues. The goal of this study was to develop and optimize a felodipine-containing microemulsion to improve the intestinal permeability and bioavailability of the drug. The felodipine microemulsions were developed with the selected components, i.e., α-linolenic acid as the oil phase, Tween 80 as a surfactant, and isopropyl alcohol as co-surfactant using Box-Behnken design and characterized for in vitro release and particle size. The optimized felodipine-loaded microemulsion was investigated for physicochemical interaction, surface morphology, intestinal permeability, rheology, cytotoxicity, cellular uptake, pharmacodynamic (electrocardiogram and heart rate variability), and pharmacokinetic studies to explore its suitability as a promising oral drug delivery system for the treatment of hypertension. The optimized felodipine-loaded microemulsion showed significantly higher (P < 0.05) apparent permeability coefficients (Papp) at 7.918 × 10-5 cm/s after 1 h, when compared with conventional formulations that are marketed tablet, drug oily solution, and drug emulsion, which showed a maximum Papp of 3.013, 4.428, and 5.335 × 10-5 cm/s, respectively. The optimized felodipine-loaded microemulsion showed biocompatibility and no cytotoxicity. Cellular uptake studies confirmed payload delivery to a cellular site on the J774.A1 cell line. The rheology study of the optimized felodipine-loaded microemulsion revealed Newtonian-type flow behavior and discontinuous microemulsion formation. In pharmacodynamic studies, significant differences in parameters were observed between the optimized felodipine-loaded microemulsion and marketed formulation. The optimized felodipine-loaded microemulsion showed significantly higher (p < 0.01) C max (7.12 ± 1.04 µg/ml) than marketed tablets (2.44 ± 1.03 µg/ml). It was found that AUClast obtained from the optimized felodipine-loaded microemulsion (84.53 ± 10.73 µg h/ml) was significantly higher (p < 0.01) than the marketed tablet (27.41 ± 5.54 µg h/ml). The relative bioavailability (Fr) of the optimized felodipine-loaded microemulsion was about 308.3% higher than that of the marketed formulation. The results demonstrate that the prepared microemulsion is an advanced and efficient oral delivery system of felodipine for the management of hypertension.
Subject(s)
Calcium Channel Blockers/administration & dosage , Drug Delivery Systems , Felodipine/administration & dosage , alpha-Linolenic Acid/administration & dosage , Administration, Oral , Animals , Biological Availability , Calcium Channel Blockers/chemistry , Calcium Channel Blockers/pharmacokinetics , Calcium Channel Blockers/pharmacology , Cell Line , Cell Survival/drug effects , Chemistry, Pharmaceutical , Drug Liberation , Emulsions , Felodipine/chemistry , Felodipine/pharmacokinetics , Felodipine/pharmacology , Heart Rate/drug effects , Intestinal Absorption , Mice , Rats, Wistar , alpha-Linolenic Acid/chemistry , alpha-Linolenic Acid/pharmacokinetics , alpha-Linolenic Acid/pharmacologyABSTRACT
Maternal docosahexaenoic acid (DHA, 22:6n-3) supplies the developing fetus during pregnancy; however, the mechanisms are unclear. We utilized pregnant rats to determine rates of DHA accretion, tissue unesterified DHA uptake and whole-body DHA synthesis-secretion. Female rats maintained on a DHA-free, 2% α-linolenic acid diet were either:1) sacrificed at 56 days for baseline measures, 2) mated and sacrificed at 14-18 days of pregnancy or 3) or sacrificed at 14-18 days as age-matched virgin controls. Maternal brain, adipose, liver and whole body fatty acid concentrations was determined for balance analysis, and kinetic modeling was used to determine brain and liver plasma unesterified DHA uptake and whole-body DHA synthesis-secretion rates. Total liver DHA was significantly higher in pregnant (95±5 µmol) versus non-pregnant (49±5) rats with no differences in whole-body DHA synthesis-secretion rates. However, liver uptake of plasma unesterified DHA was 3.8-fold higher in pregnant animals compared to non-pregnant controls, and periuterine adipose DHA was lower in pregnant (0.89±0.09 µmol/g) versus non-pregnant (1.26±0.06) rats. In conclusion, higher liver DHA accretion during pregnancy appears to be driven by higher unesterified DHA uptake, potentially via DHA mobilization from periuterine adipose for delivery to the fetus during the brain growth spurt.
Subject(s)
Docosahexaenoic Acids/metabolism , Docosahexaenoic Acids/pharmacokinetics , Liver/metabolism , Prenatal Nutritional Physiological Phenomena , Adipose Tissue/metabolism , Animals , Animals, Newborn , Body Weight , Brain/metabolism , Docosahexaenoic Acids/blood , Eating , Fatty Acids/blood , Female , Pregnancy , Rats, Long-Evans , Tissue Distribution , alpha-Linolenic Acid/metabolism , alpha-Linolenic Acid/pharmacokineticsABSTRACT
In this study, hyaluronan (HA) was grafted with alpha-linolenic acid (αLNA) by benzoyl mixed anhydrides methodology, which allowed the derivatization of HA under mild reaction conditions. The reaction was optimized and transferred from laboratory to semi-scale production. The derivative revealed an unexpected cytotoxicity after oven drying and storage at 40°C. For this reason, the storage conditions of sodium linolenyl hyaluronate (αLNA-HA) were optimized in order to preserve the beneficial effect of the derivative. Oven, spray dried and lyophilized samples were prepared and stored at -20°C, 4°C and 25°C up to 6 months. A comprehensive material characterization including stability study of the derivative, as well as evaluation of possible changes on chemical structure and presence of peroxidation products were studied by Nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (FTIR), gas chromatography-mass spectrometry (GC-MS), thermogravimetric analysis (TGA) and complemented with assessment of in vitro viability on mouse fibroblasts NIH-3T3. The most stable αLNA-HA derivative was obtained after spray drying and storage at ambient temperature under inert atmosphere. The choice of inert atmosphere is recommended to suppress oxidation of αLNA supporting the positive influence of the derivative on cell viability. The encapsulation of hydrophobic drugs of αLNA-HA were also demonstrated.
Subject(s)
Drug Carriers , Hyaluronic Acid , alpha-Linolenic Acid , Animals , Cell Survival/drug effects , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Carriers/pharmacology , Drug Stability , Hyaluronic Acid/chemistry , Hyaluronic Acid/pharmacokinetics , Hyaluronic Acid/pharmacology , Mice , NIH 3T3 Cells , alpha-Linolenic Acid/chemistry , alpha-Linolenic Acid/pharmacokinetics , alpha-Linolenic Acid/pharmacologyABSTRACT
Stroke is a worldwide major cause of mortality and morbidity. Preclinical studies have identified over 1000 molecules with brain-protective properties. More than 200 clinical trials have evaluated neuroprotective candidates for ischemic stroke yet, to date almost all failed, leading to a re-analysis of treatment strategies against stroke. An emerging view is to seek combinatory therapy, or discovering molecules able to stimulate multiple protective and regenerative mechanisms. A pertinent experimental approach to identify such candidates is the study of brain preconditioning, which refers to how the brain protects itself against ischemia and others stress-inducing stimuli. The recent discovery that nutrients like alpha-linolenic acid (ALA is an essential omega-3 polyunsaturated fatty acid required as part of our daily diet), may be an efficient brain preconditionner against stroke fosters the novel concept of brain preconditioning by nutraceuticals. This review stresses the underestimated role of nutrition in preventing and combating stroke. Although there is a consensus that increased consumption of salt, fatty foods and alcoholic beverages may promote pathologies like hypertension, obesity and alcoholism - all of which are well known risk factors of stroke - few risk factors are attributed to a deficiency in an essential nutrient in the diet. The ALA deficiency observed in the Western modern diets may itself constitute a risk factor. This review outlines how ALA supplementation by modification of the daily diet prevented mortality and cerebral damage in a rodent model of ischemic stroke. It also describes the pleiotropic ability of ALA to trigger responses that are multicellular, mechanistically diverse, resulting in neuronal protection, stimulation of neuroplasticity, and brain artery vasodilation. Overall, this review proposes a promising therapeutic opportunity by integrating a nutritional-based approach focusing on enriching the daily diet in ALA to prevent the devastating damage caused by stroke.
Subject(s)
Brain Ischemia/prevention & control , Neuroprotective Agents/therapeutic use , Stroke/prevention & control , alpha-Linolenic Acid/therapeutic use , Animals , Brain Ischemia/metabolism , Clinical Trials as Topic , Humans , Neuroprotective Agents/pharmacokinetics , Stroke/metabolism , alpha-Linolenic Acid/pharmacokineticsABSTRACT
The origin of fatty acids in milk has not been elucidated in detail. We investigated the contribution of dietary α-linolenic acid (ALA) to human milk fat, its oxidation and endogenous conversion to long-chain polyunsaturated fatty acids. Ten lactating women were given (13)C-ALA orally, and breath and milk samples were collected for a five-day period, while dietary intakes were assessed. 37.5 ± 2.7â % (M ± SE) of the tracer was recovered in breath-CO2, and 7.3 ± 1.1â % was directly transferred into milk. About 0.25â % of the tracer was found in milk long-chain polyunsaturated fatty acids. Combining intake and milk data, we estimate that about 65â % of milk ALA is directly derived from maternal diet. Thus, the major portion of milk ALA is directly derived from the diet, but dietary ALA does not seem to contribute much as a precursor to milk n-3 long-chain polyunsaturated fatty acids within the studied time period.
Subject(s)
Breast Feeding , Diet , Lactation/metabolism , Milk, Human/chemistry , alpha-Linolenic Acid/analysis , Adult , Breath Tests , Carbon Isotopes/analysis , Cholesterol/blood , Female , Humans , Isotope Labeling , Oxidation-Reduction , Triglycerides/blood , Young Adult , alpha-Linolenic Acid/administration & dosage , alpha-Linolenic Acid/pharmacokineticsABSTRACT
To investigate the biodisponibility of placental transfer of fatty acids, rats pregnant for 20 days were given tracer amounts of [(14)C]palmitic (PA), oleic (OA), linoleic (LA), α-linolenic (LNA), or docosahexaenoic acid (DHA) orally and euthanized at 0.5, 1.0, 2.0, or 8.0 h thereafter. Maternal plasma radioactivity in lipids initially increased only to decline at later times. Most of the label appeared first as triacylglycerols (TAG); later, the proportion in phospholipids (PhL) increased. The percentage of label in placental lipids was also always highest shortly after administration and declined later; again, PhL increased with time. Fetal plasma radioactivity increased with time, with its highest value at 8.0 h after DHA or LNA administration. DHA initially appeared primarily in the nonesterified fatty acids (NEFA) and PA, OA, LA, and LNA as TAG followed by NEFA; in all cases, there was an increase in PhL at later times. Measurement of fatty acid concentrations allowed calculation of specific (radio)activities, and the ratio (fetal/maternal) of these in the plasmas gave an index of placental transfer activity, which was LNA > LA > DHA = OA > PA. It is proposed that a considerable proportion of most fatty acids transferred through the placenta are released into the fetal circulation in the form of TAG.
Subject(s)
Docosahexaenoic Acids/pharmacokinetics , Fetus/metabolism , Linoleic Acid/pharmacokinetics , Oleic Acid/pharmacokinetics , Palmitic Acid/pharmacokinetics , Phospholipids/metabolism , Placenta/metabolism , Triglycerides/metabolism , alpha-Linolenic Acid/pharmacokinetics , Animals , Carbon Radioisotopes , Docosahexaenoic Acids/metabolism , Fatty Acids/metabolism , Fatty Acids/pharmacokinetics , Female , Linoleic Acid/metabolism , Oleic Acid/metabolism , Palmitic Acid/metabolism , Pregnancy , Rats , alpha-Linolenic Acid/metabolismABSTRACT
Although there is extensive information describing the positive biological effects of conjugated linoleic acid and its main isomer rumenic acid (RA; C18:2 cis 9, trans 11), and alpha-linolenic acid (ALA) and vaccenic acid (TVA), data about their bioavailability are not available. In this work, we investigated the oral absorption and disposition of these fatty acids in Wistar rats. A naturally enriched goat dairy fat (EDF) was obtained by supplementing ruminant diets with oils or oilseeds rich in polyunsaturated fatty acids (PUFA). The EDF was administered orally (single dose of 3000 mg EDF/kg body weight equivalent to 153 mg TVA/kg body weight, 46 mg RA/kg body weight and 31 mg ALA/kg body weight), and serial blood and liver samples were collected and TVA, RA and ALA concentrations determined by GC/MS. The fatty acids TVA, RA and ALA were rapidly absorbed (t1/2a, 0.36, 0.66 and 0.76 h, respectively, for plasma) and slowly eliminated (t1/2ß, 17.04, 18.40 and 16.52 h, respectively, for plasma). The maximum concentration (C max) was detected in liver > plasma > erythrocyte. Our study shows that when orally administered EDF, its components TVA, RA and ALA were rapidly absorbed and distributed throughout the body by the blood circulation to exert systemic effects.
Subject(s)
Dairy Products/analysis , Linoleic Acids, Conjugated/pharmacokinetics , Oleic Acids/pharmacokinetics , alpha-Linolenic Acid/pharmacokinetics , Administration, Oral , Animals , Goats , Linoleic Acids, Conjugated/administration & dosage , Linoleic Acids, Conjugated/blood , Liver/chemistry , Male , Oleic Acids/administration & dosage , Oleic Acids/blood , Rats , alpha-Linolenic Acid/administration & dosage , alpha-Linolenic Acid/bloodABSTRACT
Formulating healthy food rich in omega 3 fatty acids requires prior knowledge of the parameters influencing their bioavailability and their metabolic fate. In this context, we studied the effects of various emulsifiers widely used in the food industry, on the gastrointestinal lipolysis of flaxseed oil emulsions in an in vitro model and on the intestinal absorption and lymphatic secretion of alpha-linolenic acid (ALA) in rats. In vitro data showed that the emulsification of flaxseed oil with soya lecithin improved the gastric lipolysis of the oil (+30%), while the presence of Tween 80 or of sodium caseinate decreased it (-80% and -40%, respectively). The in vivo data demonstrated that the intestinal absorption and the lymphatic secretion of ALA were improved with soya lecithin (Cmax = 24 mg mL(-1)) and reduced in the presence of sodium caseinate (Cmax = 7 mg mL(-1)) compared to unemulsified flaxseed oil (Cmax = 16 mg mL(-1)); Tween 80 had no effect. In addition, the synthesized chylomicrons were notably larger and more numerous with soya lecithin whereas they were smaller in the presence of sodium caseinate (p < 0.05). This study shows that the intestinal bioavailability of ALA was increased by the emulsification of flaxseed oil with soya lecithin via an improved lipolysis, favouring the intestinal absorption of ALA and the secretion of many large chylomicrons in lymph.
Subject(s)
Chylomicrons/biosynthesis , Gastrointestinal Tract/metabolism , Lipolysis/drug effects , alpha-Linolenic Acid/chemistry , alpha-Linolenic Acid/pharmacokinetics , Animals , Biological Availability , Chemistry, Pharmaceutical , Emulsifying Agents/chemistry , Lecithins/chemistry , Linseed Oil/chemistry , Linseed Oil/pharmacokinetics , Male , Rats , Rats, Wistar , Glycine max/chemistryABSTRACT
Fatty acids are known to influence the ability of macrophages to generate reactive oxygen species (ROS). However the effect of elaidic acid (EA, 18:1 trans fatty acid) on ROS generation is not well studied. Rat peritoneal macrophages were enriched with elaidic acid by incubating the cells with 80 1M EA. The macrophages containing EA generated higher amounts of superoxide anion (O2*-), hydrogen peroxide (H2O2) and nitric oxide (NO) by 54, 123 and 237%, respectively as compared to control cells which did not contain EA. To study the competition of other C18 fatty acids with EA macrophages were incubated with EA along with stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2) and alpha-linolenic acid (ALA, 18:3). ALA significantly reduced the incorporation of EA into macrophage lipids. This also significantly reduced the generation of O2*-, H2O2, NO by macrophages. Studies were also conducted by feeding rats with diet containing partially hydrogenated vegetable fat (PHVF) as a source for EA and linseed oil (LSO) as a source for ALA. The rats were fed AIN-93 diet containing PHVF with 17% EA and incremental amounts of linseed oil for 10 weeks. The peritoneal macrophages from rats fed partially hydrogenated vegetable fat generated higher levels of O2*-, H2O2, NO by 46, 161 and 76% respectively, when compared to rats fed control diets containing ground nut oil. Macrophages from rats fed PHVF with incremental amounts of LSO produced significantly lower levels ROS in a dose dependent manner. Thus ALA reduces the higher levels of ROS generated by macrophages containing EA.
Subject(s)
Macrophages, Peritoneal/drug effects , Oleic Acid/pharmacology , Reactive Oxygen Species/metabolism , alpha-Linolenic Acid/pharmacology , Animals , Cells, Cultured , Fatty Acids/metabolism , Linseed Oil/administration & dosage , Macrophages, Peritoneal/metabolism , Male , Oleic Acids , Rats , Rats, Wistar , alpha-Linolenic Acid/pharmacokineticsABSTRACT
α-Linolenic acid (ALA), a carboxylic acid with 18 carbons and three cis double bonds, is an essential fatty acid needed for human health and can be acquired via regular dietary intake of foods that contain ALA or dietary supplementation of foods high in ALA, for example flaxseed. ALA has been reported to have cardiovascular-protective, anti-cancer, neuro-protective, anti-osteoporotic, anti-inflammatory, and antioxidative effects. ALA is the precursor of longer chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), but its beneficial effects on risk factors for cardiovascular diseases are still inconclusive. The recommended intake of ALA for cardiovascular health is reported to be 1.1-2.2g/day. Although there are limited toxicological data for ALA, no serious adverse effects have been reported. The evidence on an increased prostate cancer risk in association with dietary ALA is not conclusive. Based on the limited data currently available, it may be concluded that ALA may be beneficial as a nutraceutical/pharmaceutical candidate and is safe for use as a food ingredient.
Subject(s)
Dietary Supplements , Toxicity Tests/methods , alpha-Linolenic Acid , Animals , Anti-Inflammatory Agents/administration & dosage , Antineoplastic Agents/administration & dosage , Antioxidants/administration & dosage , Cardiovascular Diseases/prevention & control , Cardiovascular System/drug effects , Cardiovascular System/metabolism , Disease Models, Animal , Docosahexaenoic Acids/metabolism , Dose-Response Relationship, Drug , Eicosapentaenoic Acid/metabolism , Female , Humans , Male , Neuroprotective Agents/administration & dosage , Prostatic Neoplasms/etiology , Prostatic Neoplasms/pathology , Risk Factors , alpha-Linolenic Acid/adverse effects , alpha-Linolenic Acid/chemistry , alpha-Linolenic Acid/pharmacokineticsABSTRACT
The purpose of this report was to demonstrate the effect of amphiphilic polysaccharides-based self-assembling micelles on enhancing the oral absorption of low molecular weight chondroitin sulfate (LMCS) in vitro and in vivo, and identify the transepithelial transport mechanism of LMCS micelles across the intestinal barrier. α-Linolenic acid-low molecular weight chondroitin sulfate polymers(α-LNA-LMCS) were successfully synthesized, and characterized by FTIR, (1)HNMR, TGA/DSC, TEM, laser light scattering and zeta potential. The significant oral absorption enhancement and elimination half-life (t1/2) extension of LNA-LMCS2 in rats were evidenced by intragastric administration in comparison with CS and LMCS. Caco-2 transport studies demonstrated that the apparent permeability coefficient (Papp) of LNA-LMCS2 was significantly higher than that of CS and LMCS (p<0.001), and no significant effects on the overall integrity of the monolayer were observed during the transport process. In addition, α-LNA-LMCS micelles accumulated around the cell membrane and intercellular space observed by confocal laser scanning microscope (CLSM). Furthermore, evident alterations in the F-actin cytoskeleton were detected by CLSM observation following the treatment of the cell monolayers with α-LNA-LMCS micelles, which further certified the capacity of α-LNA-LMCS micelles to open the intercellular tight junctions rather than disrupt the overall integrity of the monolayer. Therefore, LNA-LMCS2 with low cytotoxicity and high bioavailability might be a promising substitute for CS in clinical use, such as treating osteoarthritis, atherosclerosis, etc.
Subject(s)
Chondroitin Sulfates/pharmacokinetics , Intestinal Absorption , Intestinal Mucosa/metabolism , alpha-Linolenic Acid/pharmacokinetics , Administration, Oral , Animals , Caco-2 Cells , Calorimetry, Differential Scanning , Cell Survival/drug effects , Chemistry, Pharmaceutical , Chondroitin Sulfates/administration & dosage , Chondroitin Sulfates/chemistry , Chondroitin Sulfates/toxicity , HT29 Cells , Half-Life , Humans , Light , Male , Micelles , Microscopy, Confocal , Microscopy, Electron, Transmission , Molecular Weight , Permeability , Proton Magnetic Resonance Spectroscopy , Rats, Sprague-Dawley , Scattering, Radiation , Spectroscopy, Fourier Transform Infrared , Technology, Pharmaceutical/methods , Thermogravimetry , alpha-Linolenic Acid/administration & dosage , alpha-Linolenic Acid/analogs & derivatives , alpha-Linolenic Acid/chemistry , alpha-Linolenic Acid/toxicityABSTRACT
In the present study we evaluated the uptake of ALA and its conversion to EPA + DHA in rats given linseed oil (LSO) in native form or as a microemulsion in whey protein or in lipoid. In a single oral dose study in which rats maintained on rodent pellets deficient in ω-3 fatty acids were intubated with 0.35 g LSO in lipoid, the amount of ALA present in lymph was increased reaching a maximum concentration of 16.23 mg/ml at 2.5 h. The amount of ALA present in lymph was increased to a maximum level of 10.95 mg/ml at 4 h in rats given LSO as a microemulsion in whey protein. When LSO was given without emulsification, the amount of ALA present in lymph was found to reach a maximum level of 7.08 mg/ml at 6 h. A similar result was observed when weaning rats were intubated with 0.15 g of LSO per day for a period of 60 days. Higher levels of ALA by 41 and 103 % were observed in lymph lipids of rats given microemulsions of LSO in whey protein and in lipoid respectively as compared to rats given LSO without pre-emulsification. Very little conversion of ALA to EPA and DHA was observed in lymph lipids but higher amounts of EPA + DHA was observed in liver and serum of rats given LSO in microemulsion form. This study indicated that ALA concentration in lymph lipids was increased when LSO was given in microemulsion form in lipoid and further conversion to EPA and DHA was facilitated in liver and serum.
Subject(s)
Animal Feed , Fatty Acids, Omega-3/biosynthesis , Linseed Oil/administration & dosage , Lymphatic System/metabolism , alpha-Linolenic Acid/pharmacokinetics , Animals , Emulsions , Male , Rats , Rats, Wistar , alpha-Linolenic Acid/metabolismABSTRACT
Flaxseed is a potent source of the n-3 fatty acid α-linolenic acid (ALA), yet most ALA is lost during ruminal biohydrogenation when ground flaxseed is fed to ruminants. Heat processing and urea formaldehyde condensation polymer (UFCP) treatment of flaxseed were investigated as possible means of protecting ALA from ruminal degradation. Ground flaxseed (GF), heated ground flaxseed (HGF), or UFCP-treated ground flaxseed (UFCPGF) were incubated for 0, 4, 8, and 12h in 4 ruminally cannulated multiparous lactating Holstein cows. Compared with GF, HGF and UFCPGF decreased ruminal disappearance of dry matter, crude protein, and ALA. Pepsin-digestible protein remaining after 12h of ruminal incubation was greater for UFCPGF and HGF than for GF. Twenty-four lactating Holstein cows (207 ± 37 d in milk, 668 ± 66 kg of body weight, and 1.33 ± 0.56 lactations) were then used in a randomized complete block design experiment with a basal feeding period to assess effects of flaxseed treatment on ALA enrichment of plasma and milk as well as lactational performance. No evidence existed that supplementation of HGF and UFCPGF affected dry matter intake, milk fat content, milk protein content, or energy-corrected milk yield, but UFCPGF marginally decreased milk yield compared with HGF. Plasma concentration of ALA was not affected by treatment. Concentrations of n-3 fatty acids and conjugated linoleic acids in milk fat were increased by UFCPGF relative to HGF, but ALA yield was not affected. Taken together, in situ results suggest that heat-treated flaxseed, with or without UFCP treatment, slowed ruminal disappearance of ALA. Feeding UFCP-treated flaxseed failed to alter ALA content of plasma or milk ALA yield relative to heating alone.
Subject(s)
Cattle/physiology , Flax/chemistry , Food Handling/methods , Formaldehyde , Polymers , Rumen/metabolism , Urea , Animal Nutritional Physiological Phenomena , Animals , Digestion , Fats/analysis , Fatty Acids, Omega-3/analysis , Female , Hot Temperature , Lactation/physiology , Milk/chemistry , Seeds/chemistry , alpha-Linolenic Acid/analysis , alpha-Linolenic Acid/metabolism , alpha-Linolenic Acid/pharmacokineticsABSTRACT
The bioavailability of α-linolenic acid (ALA) from flaxseed oil in an emulsified form v. a non-emulsified form was investigated by using two complementary approaches: the first one dealt with the characterisation of the flaxseed oil emulsion in in vitro gastrointestinal-like conditions; the second one compared the intestinal absorption of ALA in rats fed the two forms of the oil. The in vitro study on emulsified flaxseed oil showed that decreasing the pH from 7·3 to 1·5 at the physiological temperature (37°C) induced instantaneous oil globule coalescence. Some phase separation was observed under acidic conditions that vanished after further neutralisation. The lecithin used to stabilise the emulsions inhibited TAG hydrolysis by pancreatic lipase. In contrast, lipid solubilisation by bile salts (after lipase and phospholipase hydrolysis) was favoured by preliminary oil emulsification. The in vivo absorption of ALA in thoracic lymph duct-cannulated rats fed flaxseed oil, emulsified or non-emulsified, was quantified. Oil emulsification significantly favoured the rate and extent of ALA recovery as measured by the maximum ALA concentration in the lymph (Cmax = 14 mg/ml at 3 h in the emulsion group v. 9 mg/ml at 5 h in the oil group; P < 0·05). Likewise, the area under the curve of the kinetics was significantly higher in the emulsion group (48 mg × h/ml for rats fed emulsion v. 26 mg × h/ml for rats fed oil; P < 0·05). On the whole, ALA bioavailability was improved with flaxseed oil ingested in an emulsified state. Data obtained from the in vitro studies helped to partly interpret the physiological results.